ADK Diagnos Inc

In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that as a result of the issuance of 8,333,333 common shares (each, a “Share”) as part of a private placement of units announced on September 20, 2024, Mr. Tristram Coffin ceased to be an insider of the Corporation since his ownership dropped below 10%.

Immediately before the issuance of the Shares, Mr. Coffin exercised control, directly and indirectly, over 8,180,234 Shares of the Issuer, representing ownership of 10.04% on an undiluted basis.

The issuance of the Shares remains subject to the TSX Venture approval.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of advanced image enhancement algorithms which make standard retinal images sharper, clearer and easier to read.

Additional information is available at www.diagnos.com and www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. Marc-André Massue, CFO
DIAGNOS Inc.
Tel: 450-678-8882 ext. 235